A HelloNation Article Explains When Mini Dental Implants Can Avoid Bone Grafting and When Grafting May Still Be Needed. BLACKSBURG, Va., Sept. 14, 2026 /PRNewswire/ -- Can mini dental implants always avoid the need for bone grafting? A HelloNation article has been published that answers this question, walking through how bone loss is evaluated before recommending mini implants. The article features insight from Dr. Raymond Munz, Denture and Implant Expert at Blacksburg Denture and Implant Center

Enables routine 50+ parameter experiments with BD SpectralFX™ Technology, accelerating breakthrough discoveries in the fight against cancer and other diseases. Minimizes instrument and user differences with first-of-its-kind FACSTruQ™ Technology, achieving industry-leading standardization for greater confidence in results. Integrated autoloader and BD FACSChorus™ Software speeds time to insight for new and experienced users. MILFORD, Mass., Sept. 14, 2026 /PRNewswire/ -- Waters Corporation (N

The designation covers Bright Path's end-to-end U.S. production of two hospital medicines in chronic shortage, the first proof that essential medicines can be made in America, in most cases at prices that beat China and India MESA, Ariz., Sept. 14, 2026 /PRNewswire/ -- Bright Path, a U.S. pharmaceutical manufacturer, today announced that the U.S. Food and Drug Administration (FDA) has granted the company an Advanced Manufacturing Technology (AMT) designation, the agency's pathway for encouraging

Study informed by encouraging exploratory efficacy findings and a favorable safety profile in the prior Phase 3 trial Approximately 120 participants with severe postpartum depression (PPD) planned; first participant dosing expected in early Q4 2026 Company expects existing resources to support BLOOM SALT LAKE CITY, Sept. 14, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced the initiation o

TAMPA, Fla., Sept. 14, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that the U.S. Food and Drug Administration (FDA) has given clearance to TuHURA's Investigational New Drug (IND) application for its TBS-2025 VISTA-inhibiting antibody for molecularly defined subsets of Acute Myeloid Leukemia (AML) and other blood-related cance

Final overall survival analysis reports median survival of 34.3 months with amivantamab-chemotherapy versus 27.9 months with chemotherapy SEOUL, Republic of Korea, Sept. 14, 2026 /PRNewswire/ -- Results from the Phase III PAPILLON study show that first-line amivantamab plus carboplatin-pemetrexed (amivantamab-chemotherapy) was associated with numerically longer overall survival compared with chemotherapy in patients with previously untreated advanced non-small cell lung cancer (NSCLC) with EGFR

Fashion industry shift puts new focus on bio-based and innovative textiles as Kraig Labs scales recombinant spider silk for potential luxury and performance applicationsANN ARBOR, Mich., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("the Company", "Kraig Labs", or "Kraig's"), a world leader in spider silk technology*, today highlighted the growing opportunity for advanced biomaterials in fashion as New York Fashion Week begins. The Council of Fashion Desi

BOSTON--(BUSINESS WIRE)--Seaport Therapeutics, Inc. (Nasdaq: SPTX) (“Seaport” or the “Company”), a clinical-stage therapeutics company that is inventing and developing novel neuropsychiatric medicines, today announced that members of its management team will participate in a series of additional upcoming investor conferences in September, including a company presentation and panel discussion featuring Co-Founder and Chief Executive Officer, Daphne Zohar, at the Goldman Sachs Life Sciences Sympos

Texas-based company is designed to coordinate U.S. development, pharmaceutical-grade supply and potential clinical sponsorship activities through a dedicated Psyence BioMed entityHIGHLIGHTS Texas-based company established as dedicated U.S. vehicle for regulated ibogaine developmentPositioned to hold U.S. rights to PsyLabs’ pharmaceutical-grade ibogaine, subject to completion of definitive licensing arrangementsDesigned to coordinate supply, manufacturing, regulatory and potential clinical devel

As part of a multi-product collaboration, Asimov’s CHO Edge system enabled a high performance cell line for a first-in-class bispecific antibody, achieving clonal titers of over 10 g/L in a platform fed-batch process BOSTON, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Asimov, the company building an AI-native synthetic biology platform to advance therapeutic development, today announced a cell line development partnership with Sidewinder Therapeutics, a biopharmaceutical company pioneering the developm